Loading people...
Andrea van Elsas is a Venture Partner at Third Rock Ventures based in Oss, Netherlands, where he focuses on early-stage life sciences investments, company creation, and advancing novel therapeutic modalities in immuno-oncology. He holds a Ph.D. in immunology from Leiden University and completed postdoctoral research at UC Berkeley, co-inventing foundational patents for the FDA-approved checkpoint inhibitor ipilimumab. During twelve years at Organon, Schering-Plough, and Merck, he directed the tumor immunology portfolio and played a pivotal role in the early development of the blockbuster cancer immunotherapy pembrolizumab, also known as Keytruda. He later co-founded BioNovion, acquired by Aduro Biotech in 2015, and subsequently served as Aduro's Chief Scientific Officer. Before assuming his current venture capital role, he served as Chief Scientific Officer for Abata Therapeutics and joined the Scientific Advisory Board of InteRNA Technologies.
Andrea van Elsas stands as a pivotal figure in the biotechnology investment landscape, serving as a Venture Partner at Third Rock Ventures. In this crucial role, she applies her profound scientific acumen and extensive industry experience to scout, evaluate, and nurture early-stage life science companies. Third Rock Ventures is renowned for its company creation model, and Andrea plays an integral part in identifying promising scientific breakthroughs and assembling the teams and strategies required to build successful ventures from the ground up.
Her investment focus areas are deeply rooted in her scientific background, primarily encompassing immunology and oncology. Andrea is particularly interested in novel therapeutic modalities, next-generation drug discovery platforms, and innovative approaches that address significant unmet medical needs. Her work at Third Rock involves collaborating closely with entrepreneurs and scientists to develop robust scientific strategies, build strong management teams, and secure the necessary resources to advance groundbreaking therapies from concept to clinic.
Andrea's career background is exceptionally distinguished, marked by significant contributions to the field of immunology. She holds a Ph.D. in immunology and has a rich history in both academic research and pharmaceutical development. Prior to her role at Third Rock Ventures, she held leadership positions at various biotech companies, where she was instrumental in advancing drug discovery programs. Most notably, Andrea is widely recognized for her foundational research on CTLA-4 blockade, a discovery that revolutionized cancer immunotherapy. Her pioneering work directly led to the development of ipilimumab (Yervoy), the first checkpoint inhibitor approved for melanoma, which marked a paradigm shift in cancer treatment. This seminal contribution underscores her deep understanding of drug development and her ability to identify and champion truly transformative scientific concepts.
At Third Rock Ventures, Andrea continues to apply this visionary perspective, seeking out companies that have the potential to make a similar impact. While specific "notable investments" in the traditional sense might be proprietary or less publicly detailed for a Venture Partner involved in company creation, her influence is felt across the portfolio companies she helps shape, particularly those focused on immune-oncology and autoimmune diseases. Her expertise is invaluable in guiding these companies through the complex stages of preclinical and clinical development, ensuring they are well-positioned to bring life-changing medicines to patients. Through her strategic insights and scientific leadership, Andrea van Elsas remains a driving force in advancing the next generation of biotech innovation.
Andrea van Elsas invests in early-stage biotechnology companies, with a primary focus on immunology, oncology, novel therapeutic modalities, and advanced drug discovery platforms.
Andrea van Elsas works as a Venture Partner at Third Rock Ventures, a leading life sciences venture capital firm.
